Transient Ischemic Attack News and Research

RSS
A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.
TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

Gore REDUCE Clinical Study investigates PFO in stroke patients

Gore REDUCE Clinical Study investigates PFO in stroke patients

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Dabigatran etexilate benefits AF patients with previous stroke or transient ischemic attack

Dabigatran etexilate benefits AF patients with previous stroke or transient ischemic attack

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

New guidelines feature various key updates for stroke or TIA survivors

New guidelines feature various key updates for stroke or TIA survivors

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

Mexican-American stroke survivors with atrial fibrillation at increased risk for second stroke

Mexican-American stroke survivors with atrial fibrillation at increased risk for second stroke

Boehringer Ingelheim announces sub-analysis result of RE-LY trial

Boehringer Ingelheim announces sub-analysis result of RE-LY trial

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Healthy heart may slow down aging of brain: Study

Healthy heart may slow down aging of brain: Study

NMT Medical reports $2.6 million net income for second-quarter 2010

NMT Medical reports $2.6 million net income for second-quarter 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Gore provides update on REDUCE Clinical Study of HELEX Septal Occluder for PFO closure

Gore provides update on REDUCE Clinical Study of HELEX Septal Occluder for PFO closure

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

Daiichi Sankyo, Eli Lilly respond to ACCF/AHA clinical alert on FDA's clopidogrel boxed warning

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Investment report on NMT Medical released

Investment report on NMT Medical released